As the first approved IL-1 inhibitor (2001), anakinra remains a basic drug for the treatment of refractory RA and neonatal multi-system inflammatory diseases through inhibiting the binding of IL-1α/β to receptors [5]. Here, IL1B is linked to rheumatoid arthritis.